GSK’s Benlysta shows sustained disease control in study
admin 19th June 2017 Uncategorised 0Adding GSK’s Benlysta to standard of care in patients with lupus prolonged control of disease activity, according to newly-released findings of a 10-year continuation study.
More: GSK’s Benlysta shows sustained disease control in study
Source: News